NCT00202774View on ClinicalTrials.gov

Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

August 31, 2004

Study Completion Date

December 31, 2005

Conditions
Colorectal Cancer
Interventions
DRUG

(capecitabine, oxaliplatin, 5-fluorouracil)

Trial Locations (1)

28046

Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD), Madrid

All Listed Sponsors
lead

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

OTHER

NCT00202774 - Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter